Show simple item record

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

dc.contributor.authorHislop, Jennifer
dc.contributor.authorMowatt, Graham
dc.contributor.authorSharma, Pawana
dc.contributor.authorFraser, Cynthia
dc.contributor.authorElders, Andrew
dc.contributor.authorJenkinson, David
dc.contributor.authorVale, Luke
dc.contributor.authorPetty, Russell
dc.date.accessioned2012-06-08T11:00:00Z
dc.date.available2012-06-08T11:00:00Z
dc.date.issued2012-06
dc.identifier.citationHislop , J , Mowatt , G , Sharma , P , Fraser , C , Elders , A , Jenkinson , D , Vale , L & Petty , R 2012 , ' Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose ' , Journal of Gastrointestinal Cancer , vol. 43 , no. 2 , pp. 168-176 . https://doi.org/10.1007/s12029-011-9325-6en
dc.identifier.issn1941-6628
dc.identifier.otherPURE: 13512938
dc.identifier.otherPURE UUID: 220ee7d8-35d9-4225-b8f3-1ba7e6dbe804
dc.identifier.otherScopus: 84863877145
dc.identifier.urihttp://hdl.handle.net/2164/2482
dc.descriptionPMID: 21971958 [PubMed - indexed for MEDLINE] PMCID: PMC3348468 Free PMC Article This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are crediteden
dc.format.extent9
dc.language.isoeng
dc.relation.ispartofJournal of Gastrointestinal Canceren
dc.rightsThe original publication is available at www.springerlink.com. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectGISTen
dc.subjectgastrointestinal stromal tumoursen
dc.subjectunresectableen
dc.subjectmetastaticen
dc.subjectcanceren
dc.subjectimatiniben
dc.subjectsunitiniben
dc.subjectantineoplastic agentsen
dc.subjectbenzamidesen
dc.subjectclinical trials as topicen
dc.subjectdisease progressionen
dc.subjectdose-response relationshipen
dc.subjectgastrointestinal stromal tumorsen
dc.subjecthumansen
dc.subjectindolesen
dc.subjectpiperazinesen
dc.subjectpyrimidinesen
dc.subjectpyrrolesen
dc.subjecttreatmemnt outcomeen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subject.lccRC0254en
dc.titleSystematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Doseen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1007/s12029-011-9325-6
dc.identifier.vol43en
dc.identifier.iss2en


Files in this item

Thumbnail
Name:
Hislop_2012.pdf
Size:
213.4Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record